Agenus Inc. , a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies. It is also developing checkpoint modulating antibody candidates targeting GITR, OX40, TIM-3, LAG-3, and others. In addition, the company develops vaccine programs, including Prophage cancer vaccine candidate; AutoSynVax, a synthetic neo-antigen; and PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes. Further, it develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. Additionally, the company engages in the development of CTLA-4 and PD-1 antagonists; and anti-CTLA-4, CD137, and anti-TIGIT antibodies, as well as various multi-specific antibodies that are under various stages of development. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies; and partnership with Phyton Biotech. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

This week @MassGovernor Baker proclaimed January “Cervical Cancer Awareness Month.” We at $AGEN are recognizing Kate Weissman who is championing this cause. @Agenus_Bio is advancing NextGen I-O antibodies (AGEN1181) to fight cervical cancer. #CervicalCancerAwarenessMonth

LATEST NEWSLETTER: #CervicalCancerAwarenessMonth @Agenus_Bio is committed to conquering advanced #cervicalcancer with new I-O therapies and combinations. https://agenusbio.com/wp-content/uploads/2020/01/NL-200121-Iss2-Cervical-Cancer-v2.pdf

.@GileadSciences discloses new oncology targets with first-in-class bispecific discovered by and exclusively licensed from @Agenus_Bio. More than 14 discoveries from $AGEN are in the clinic #innovation #cancer
https://agenusbio.com/wp-content/uploads/2019/10/NEW-PIPELINE-SLIDE-07-24-19-v10.jpg

$AGEN appoints Dr. Jennifer Buell to President & COO of Agenus. "Jen’s tenure @Agenus_Bio, exceptional leadership & cultural attributes, and deep understanding of our science & operations makes her the top candidate for this new position" said @garo_armen https://investor.agenusbio.com/2020-01-09-Agenus-Announces-the-Appointment-of-Dr-Jennifer-Buell-to-the-position-of-President-and-COO

$AGEN at #JPM20. On track to file 2 BLAs during 2020 and novel IO combinations in the clinic. https://agenusbio.com/wp-content/uploads/2020/01/NL-200107-2019-year-in-review-v.2.pdf for more, contact us at: investorrelations@agenusbio.com
See you in San Francisco!
#JPM2020 #BioWeekSF

$AGEN Commences Phase 1 trial with AGEN1223 - a novel bispecific designed to deplete Tregs from the tumor microenvironment. First patient dosed DEC19, study ongoing with combinations planned. https://investor.agenusbio.com/2020-01-08-Agenus-Commences-Phase-1-trial-with-AGEN1223 #Immunology #innovation

NEWSLETTER 2020: Reports an exciting 2019 and reveals a look into what's to come in 2020:
(2) planned BLA filings in 2L CC
(2) Novel discoveries to IND
(6) clinical programs with data, including AGEN1181 + balstilimab https://agenusbio.com/wp-content/uploads/2020/01/NL-200107-2019-year-in-review-v.2.pdf #immunoncology #innovation

We are excited to announce in collaboration with @Agenus_Bio, Dr. Steven O'Day, Executive Director of JWCI, is working on a combination study with two novel CTLA-4 and PD-1 immunotherapy drugs for patients with advanced cancers. Read the press release: http://provhealth.org/60101XPia

Load More...

FULL NAME*

What's Your Role?*

WORK EMAIL*

COMPANY NAME*

Company Description*

HOW'D YOU HEAR ABOUT US?

DETAILS ABOUT YOUR GOALS

Agenus Inc.

3 Forbes Road
Lexington, MA 02421

+1 (781) 674-4400

www.agenusbio.com

January 2020
S M T W T F S
« Nov    
 1234
567891011
12131415161718
19202122232425
262728293031  

©2020 ALIGNMT LLC | Alignment Strategy | Mergers & Acquisitions | Investor Relations

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending

Log in with your credentials

or    

Forgot your details?

Create Account